达克替尼

Description

dacomitinib · CAS 1110813-31-4 · C24H25ClFN5O2. UNII 2XJX250C20. Boiling Point: 665.7; Melting Point: 184-187 ºC; Solubility: <1 mg/mL.

Identification

CAS Registry Number	1110813-31-4
PubChem CID	11511120
Molecular formula	C24H25ClFN5O2
IUPAC name	(E)-N-[4-(3-chloro-4-fluoroanilino)-7-methoxyquinazolin-6-yl]-4-piperidin-1-ylbut-2-enamide
UNII (FDA)	2XJX250C20

Computed Descriptors

Molecular Weight	469.9
XLogP3	4.4
Hydrogen Bond Donor Count	2
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	7
Exact Mass	469.1680809
Monoisotopic Mass	469.1680809
Topological Polar Surface Area	79.4
Heavy Atom Count	33
Formal Charge	0

Physical & Chemical Properties

Boiling Point	665.7
Melting Point	184-187 ºC
Solubility	<1 mg/mL
LogP	3.92

Documented Uses

• Dacomitinib is a multi-kinase receptor inhibitor used in the therapy of cases of non-small cell lung cancer that harbor activating mutations in the epidermal growth factor receptor gene (EGFR). Dacomitinib is associated with high rate of transient serum aminotransferase elevations during therapy but has not been linked to instances of clinically apparent acute liver injury.
• Breast Feeding; Lactation; Milk, Human; Antineoplastic Agents; Enzyme Inhibitors; Tyrosine Kinase Inhibitors
• Dacomitinib is approved to treat:
• • Non-small cell lung cancer (NSCLC) that has metastasized (spread to other parts of the body). It is used as first-line treatment in patients whose tumors have certain EGFRgenemutations.
• Dacomitinib is also being studied in the treatment of other types of cancer.
• Avoid grapefruit products. Grapefruit inhibits CYP3A4 metabolism, which may increase the serum concentration of dacomitinib.

Synonyms

Dacomitinib; 1110813-31-4; PF-00299804; Dacomitinib anhydrous; dacomitinibum; Vizimpro; PF-299804; 2XJX250C20; pf00299804; PF 00299804-03; PF-00299804-03; (2e)-N-{4-[(3-Chloro-4-Fluorophenyl)amino]-7-Methoxyquinazolin-6-Yl}-4-(Piperidin-1-Yl)but-2-Enamide; CHEBI:132268; DTXSID50149493; (2E)-N-(4-((3-CHLORO-4-FLUOROPHENYL)AMINO)-7-METHOXYQUINAZOLIN-6-YL)-4-PIPERIDIN-1-YLBUT-2-ENAMIDE; 2-Butenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)-4-(1-piperidinyl)-, (2E)-

Frequently Asked Questions

What are the CAS number and molecular formula of dacomitinib?

CAS 1110813-31-4; molecular formula C24H25ClFN5O2; molecular weight — g/mol.

What other names is dacomitinib known by?

Dacomitinib, 1110813-31-4, PF-00299804, Dacomitinib anhydrous, dacomitinibum, Vizimpro.

What are the key physical properties of dacomitinib?

Boiling Point: 665.7; Melting Point: 184-187 ºC; Solubility: <1 mg/mL; LogP: 3.92.

Facts on this page are taken from PubChem (US National Library of Medicine) and Wikidata. Grade-specific data — assay, moisture, particle size, packaging, shelf life — is issued per batch on the COA and is not published here.